Why Affymax Shares Popped

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of biopharmaceutical company Affymax (Nasdaq: AFFY  ) jumped as much as 11% today after the company reported better-than-expected third-quarter results.

So what: For the quarter, Affymax reported a 3% increase in revenue to $13.6 million, and quarterly loss of $0.68 per share compared to a loss of $0.28 per share last year. Both figures slid ever-so-slightly past Wall Street's expectations for a loss of $0.70 on revenue of $13.4 million. Consistent with its previous guidance, Affymax doesn't anticipate receiving any additional collaborative revenue in 2012, but it did note that $10.4 million of its $13.6 million in revenue came from payments by Takeda Pharmaceuticals concerning its partnership on Omontys, an injectable anemia treatment.

Now what: With drug approval only being half the battle, it appears that investors are just happy to see revenue streaming in from initial Omontys sales. However, I have to point out that with only one FDA-approved drug on pharmacy shelves and losses mounting, Affymax's run higher may be a bit overdone. It's a bit difficult to support a company that's quadrupled in price and is still two years away, at minimum, from being profitable. Needless to say, I'm perfectly happy remaining an innocent bystander here.

Craving more input? Start by adding Affymax to your free and personalized watchlist so you can keep up on the latest news with the company.


Read/Post Comments (1) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On November 11, 2012, at 10:07 PM, mbracket123 wrote:

    Fool,

    Losses are mounting as expected on initial roll-out. Did you listen to the quarterly call - not sure I have heard better news in a long time - product acceptance, sales #s, strategic wins...They are funded to profitability for sure.

    Your conclusion that it is difficult to support a company whose stock price has quadrupled in price is baseless. Its was a binary decision on whether Omontys was approved or not so of course it could have quadrupled. They were a pre-rev company! Guys, come on that sounds really amateurish comparing to an ongoing entity.

    Affy is executing on a major incursion into Amgen 20 year monopoly and they have every single advantage in a comparison chart - and their already deliving and have forecast that seems to support. You didnt comment at all on why you think the core product / business doesnt look good. In fact, your naivety shows when you said "but it did note that $10.4 million of its $13.6 million in revenue came from payments by Takeda Pharmaceuticals concerning its partnership on Omontys, an injectable anemia treatment." Hello... that is their initial sales/profit. Mike

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2105139, ~/Articles/ArticleHandler.aspx, 9/20/2014 10:01:30 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement